TL;DR
- Company: Excelvision, a Fareva facility in Annonay, France — maker of sterile ophthalmic drug products.
- Date: Warning letter issued June 25, 2026; posted to FDA's public database June 30, 2026.
- Classification: CGMP / Finished Pharmaceuticals / Adulterated, under 501(a)(2)(B) of the FD&C Act.
- Key citations: Failure to investigate discrepancies (211.192), failure to prevent microbial contamination in sterile products (211.113(b)), and facility construction/equipment-maintenance and cleaning/disinfection failures (211.42(c)(10)(i), (v), and (vi)).
- Consequence: Firm already sits on Import Alert 66-40 as of April 27, 2026, agreed to a voluntary recall of affected products following an April 7, 2026 FDA teleconference, and FDA flags this as a repeat violation following a 2024 warning letter.
| Company | Location | Letter # | Issued | Issuing Office | Inspection Dates | Classification |
|---|---|---|---|---|---|---|
| Excelvision (Fareva) | 27 Rue de la Lombardiere, Annonay, France | 726714 | June 25, 2026 | CDER | January 12–22, 2026 | CGMP / Finished Pharmaceuticals / Adulterated |
Mold. Black particulate. Flaking black paint on equipment that touches sterile caps. That's not a hypothetical risk profile; it's what FDA inspectors documented on the floor of a facility manufacturing sterile eye drops. The FDA Warning Letter, June 25, 2026 lays it out in plain terms, and the facility was already sitting on an import alert before the letter even posted.
Excelvision, operating as a Fareva site at 27 Rue de la Lombardiere in Annonay, France (FEI 3007058211), makes both prescription and OTC sterile ophthalmic products. FDA inspected the site January 12–22, 2026. The firm submitted a response to the Form FDA 483 on February 12, 2026. FDA found that response, and the underlying quality systems, insufficient.
What FDA found: the CFR-by-CFR breakdown
The letter centers on four regulatory failures, each tied to a specific CFR section.
21 CFR 211.192 — failure to investigate discrepancies. When something goes wrong in a batch, a deviation, an out-of-spec result, an unexplained failure, CGMP requires a thorough investigation into the cause. FDA found Excelvision wasn't doing this reliably, which means problems could recur without the firm ever understanding why.
21 CFR 211.113(b) — failure to prevent microbiological contamination. This is the core violation for a sterile-drug manufacturer. The regulation requires validated procedures, for both aseptic processing and sterilization, that actually keep products sterile. FDA's inspectors didn't have to infer a gap in validation; they saw the physical evidence of one, according to the FDA Warning Letter, June 25, 2026.
21 CFR 211.42(c)(10)(i) and (vi) — facility construction and equipment-maintenance failures. These sections require smooth, hard, easily cleanable surfaces in aseptic areas and an adequate system for maintaining the equipment used to control aseptic conditions. Inspectors documented ceilings and partitions made of a material the firm itself described as "not waterproof" and unable to be decontaminated, multiple water incursions in classified areas between January 2024 and January 2026, and mold recoveries in routine production data over the same window — plus a cap-handling component coated in what appeared to be flaking black paint and equipment near sterile components and open bottles that appeared corroded. In a sterile ophthalmic operation, corroded equipment and flaking paint near product-contact surfaces aren't cosmetic issues; they're direct contamination pathways.
21 CFR 211.42(c)(10)(v) — inadequate cleaning and disinfection system. FDA found the firm doesn't sterilize critical equipment components that contact container/closure parts between batches, relying instead on disinfection with sporicide. FDA called that an inadequate substitute for a validated sterilization program on parts that directly touch sterile product constituents.
FDA also recommended, under 21 CFR 211.34, that the firm engage a qualified CGMP consultant. That is language FDA typically reserves for firms whose internal quality function has demonstrably failed to catch or fix systemic problems.
Why the repeat-violation framing matters
This is the detail that should worry anyone tracking this firm: FDA explicitly connects this letter to a prior one. A previous warning letter, WL 320-25-70, cited similar severe CGMP violations at the same type of operation. FDA also references a November 2024 inspection, after which the firm received a substantial number of contamination-related complaints.
FDA didn't just list these as background. It used them to frame the current findings as evidence that the firm's oversight and quality systems remain inadequate. That is a materially different posture than a first-time citation. A single warning letter can be read as a snapshot of a bad inspection. A second letter citing the same category of failure, after complaints already flagged the problem, reads as a pattern FDA believes the firm has failed to correct. For compliance teams, that repeat-violation language is often the clearest signal of how FDA will treat the next inspection, and how skeptically it will read the next corrective action plan.
The voluntary recall FDA prompted
On April 7, 2026, FDA held a teleconference with the firm recommending it consider removing any batches of the affected drug products still in U.S. distribution. The firm agreed, and issued voluntary recalls of all affected products then in U.S. distribution, citing lack of sterility assurance — the same pattern FDA has used with other sterile-manufacturing warning letter recipients this year (see the Pharmathen International warning letter for a comparable recall sequence). The recall predates the warning letter's own public posting by nearly three months, another reminder that a company's import-alert and recall history is often a faster signal than the warning letter itself.
What the Import Alert means
FDA placed Excelvision on Import Alert 66-40 on April 27, 2026, nearly two months before the warning letter itself was posted. Import Alert 66-40 covers drugs that appear to be adulterated due to CGMP deviations, and it authorizes detention without physical examination of shipments from the listed facility.
Practically, that means product from this site can already be stopped at the U.S. border, independent of whatever the firm does in response to the warning letter. The letter adds a second consequence: FDA may withhold approval of new drug applications that list this facility as a manufacturer, which affects not just Excelvision/Fareva but any sponsor relying on this site in a pending ANDA or NDA. The letter also references GDUFA III commitments and Post-Warning Letter Meeting eligibility, which govern how and when the firm can formally engage FDA on remediation timelines.
What compliance teams should take from it
If your supply chain includes this facility, or any facility with a documented prior warning letter, treat that history as a leading indicator, not a closed chapter. FDA is reading recurrence as a systems failure, not a one-off. Audit programs should specifically probe whether corrective actions from a firm's most recent 483 or warning letter were structural (equipment replacement, revalidated aseptic processes, redesigned investigation procedures) or superficial (a memo and a retraining session). Firms citing prior contamination complaints without matching capital investment in facility remediation are a red flag worth escalating internally, regardless of what their current CGMP certificate says.
FAQ
What products are affected by the Excelvision warning letter?
The letter covers sterile ophthalmic drug products, both prescription and OTC. FDA redacts the specific product identifiers in the public letter as (b)(4).
Is Excelvision/Fareva currently allowed to ship product to the U.S.?
The firm is on Import Alert 66-40 as of April 27, 2026, which allows FDA to detain shipments without physical examination. This alert predates the warning letter's public posting.
Has this facility been cited before?
Yes. FDA references a prior warning letter (WL 320-25-70) covering similar CGMP violations, plus a November 2024 inspection followed by a substantial volume of contamination-related complaints.
Did this warning letter lead to a product recall?
Yes. FDA held a teleconference with the firm on April 7, 2026 recommending removal of affected batches from the U.S. market, and the firm subsequently issued voluntary recalls of all affected drug products then in U.S. distribution, citing lack of sterility assurance.
Updated 2026-08-23: added the April 7, 2026 FDA teleconference and resulting voluntary recall (confirmed via a direct re-fetch of the full FDA warning letter text), and corrected the facility/cleaning CFR citation from 211.42(c)(10)(iv)/(v) to the letter's actual citations, 211.42(c)(10)(i), (v), and (vi), split across the two distinct violations they apply to. No FDA close-out letter or other public follow-up action was found for this facility as of this update (checked directly against Argus's Supabase warning-letter database and a fresh WebSearch/fda.gov check).
Source: FDA Warning Letter, June 25, 2026. Byline: Andy Gaber, Founder. Published 2026-07-04.